LB Pharmaceuticals moves LB-102 Phase 3 schizophrenia topline data to H1 2027

Faster-than-expected enrollment in the NOVA-2 trial prompted the updated timeline, with a pre-NDA meeting with the FDA planned in the second half of 2027.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.